Latest Nyctalopia Stories
Today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting includes a report on beta carotene's ability to improve vision in people with certain incurable retinal diseases.
Neurobiologists funded by the Office of Naval Research (ONR) have discovered a potential cure for degenerative vision diseases leading to terminal blindness.
TOKYO, July 15 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 15 the completion of the Phase II clinical study on the ophthalmic solution UF-021 (product name Ocuseva (TM)) under development as a therapeutic drug for retinitis pigmentosa (Note 1).
TOKYO, June 3 /PRNewswire/ -- We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva (TM), which we are developing as a therapeutic drug for retinitis pigmentosa (note 1), has been completed. Retinitis pigmentosa is an intractable disease where therapeutic drugs or therapeutic methods have not been established yet.
Moran Eye Center researchers have found gene mutations that result in retinitis pigmentosa (RP), one of the leading causes of blindness.
- The abrogation of a law by a higher authority; annulment.